Rallybio (RLYB) Assets Average (2021 - 2026)
Rallybio (RLYB) posted Assets Average of $58.4 million for Q1 2026, down 10.15% sequentially from $65.0 million in Q4 2025, and down 7.42% YoY from $63.0 million in Q1 2025.
Rallybio (RLYB) Assets Average (2021 - 2026) Analysis & Trends
Rallybio has reported Assets Average for 6 years, with the latest figure at $58.4 million in Q1 2026.
- Quarterly Assets Average fell 7.42% year-over-year to $58.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.4 million (down 7.42% YoY) and the FY2025 annual result came in at $65.2 million, down 29.04% from the prior year.
- Assets Average slipped to $58.4 million in Q1 2026 per RLYB's latest filing, from $65.0 million in the prior quarter.
- Over five years, Assets Average peaked at $175.8 million in Q1 2022 and troughed at $54.5 million in Q2 2025.
- A 5-year average of $112.0 million and a median of $107.5 million in 2024 frame the typical range for Assets Average.
- The sharpest annual moves came in 2023 and 2025: Assets Average declined 2.5% in 2023, then sank 43.17% in 2025.
- Over 5 years, Assets Average stood at $162.1 million in 2022, then retreated by 23.23% to $124.4 million in 2023, then slumped by 40.87% to $73.6 million in 2024, then retreated by 11.69% to $65.0 million in 2025, then fell by 10.15% to $58.4 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $58.4 million, $65.0 million, and $59.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Rallybio | 94.32 Mn | 94.32 Mn | - | 76.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76.27 Mn |
| Mar 31, 2026 | 58.37 Mn |
| Dec 31, 2025 | 64.96 Mn |
| Sep 30, 2025 | 59.33 Mn |
| Jun 30, 2025 | 54.49 Mn |
| Mar 31, 2025 | 63.05 Mn |
| Dec 31, 2024 | 73.56 Mn |
| Sep 30, 2024 | 85.72 Mn |
| Jun 30, 2024 | 95.90 Mn |
| Mar 31, 2024 | 107.49 Mn |
| Dec 31, 2023 | 124.41 Mn |
| Sep 30, 2023 | 140.39 Mn |
| Jun 30, 2023 | 154.95 Mn |
| Mar 31, 2023 | 171.38 Mn |
| Dec 31, 2022 | 162.05 Mn |
| Sep 30, 2022 | 149.64 Mn |
| Jun 30, 2022 | 162.48 Mn |
| Mar 31, 2022 | 175.77 Mn |
| Dec 31, 2021 | 188.03 Mn |
| Sep 30, 2021 | 156.98 Mn |